共 43 条
- [31] Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER studyCANCER RESEARCH, 2023, 83 (05)Jhaveri, KomalWang, Hwei-ChungMa, CynthiaLim, ElgeneTao, Jessica J.Manso, LuisPierga, Jean-YvesParajuli, RiteshGilarranz, Yolanda JerezLu, Yen-ShenBeeram, MuralidharLarson, TimDhakal, AjayIsmail-Khan, RoohiKaracsonyi, ClaudiaCao, ShanshanOsborne, CynthiaEstrem, Shawn T.Nguyen, BastienLi, Yujia
- [32] Reflecting time dependency in hazard rates to analyse the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor-positive (HR+) postmenopausal women: The U.S. perspectiveJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Karnon, J.Mody-Patel, N.Kaura, S.
- [33] Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) : 2350 - U82Wolmark, NormanMamounas, Eleftherios P.Baehner, Frederick L.Butler, Steven M.Tang, GongJamshidian, FaridSing, Amy P.Shak, StevenPaik, Soonmyung
- [34] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trialEUROPEAN JOURNAL OF CANCER, 2018, 92 : S3 - S3Harbeck, N.Vazquez, R. VillanuevaTripathy, D.Lu, Y.De Laurentiis, M.Kuemmel, S.Taylor, D.Bardia, A.Hurvitz, S.Chow, L.Im, S.Franke, F.Hughes, G.Miller, M.Kong, O.Chandiwana, D.Colleoni, M.
- [35] First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trialCANCER RESEARCH, 2018, 78 (04)Tripathy, DebuSohn, JoohyukIm, Seock-AhColleoni, MarcoFranke, FabioBardia, AdityaHarbeck, NadiaHurvitz, SaraChow, LouisLee, Keun SeokCampos-Gomez, SaulVazquez, Rafael VillanuevaJung, Kyung HaeCarlson, GaryHughes, GarethDiaz-Padilla, IvanGerma, CarolineHirawat, SamitLu, Yen-Shen
- [36] Risk of health-related quality of life events from pain and fatigue among patients with hormone receptor-positive HER-2 negative metastatic breast cancer treated with CDK 4/6 inhibitor.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31)Han, Myat M.Thein, Kyaw ZinZaw, MyoTun, AungD'Cunha, PaulHardwicke, Fred L.Jones, Catherine
- [37] Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Wang, JianiZhang, QingyuanHu, XichunLi, QingSun, TaoLi, WeiOuyang, QuchangWang, JingfenTong, ZhongshengYan, MinLi, HuipingZeng, XiaohuaShan, ChangpingWang, XianZhang, JianZhang, YueZhang, LiangTian, YingShang, HongyanXu, Binghe
- [38] POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Baird, Richard D.Van Rossum, AnnelotOliveira, MafaldaBeelen, KarinGarcia-Corbacho, JavierMandjes, Ingrid A. M.Vallier, Anne-Laurevan Werkhoven, Erik D.Kumar, Sanjeev Srinivasvan Tinteren, HarmBeddowes, EmmaRosing, HildeSchrier, MarietteSchultink, Aurelia de VriesSaura, CristinaBernards, ReneTabernero, JosepCortes, JavierCaldas, CarlosLinn, Sabine C.
- [39] Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trialCANCER RESEARCH, 2022, 82 (04)Bardia, AdityaNeven, PatrickStreich, GuillermoMontero, Alberto J.Forget, FredericMouret-Reynier, Marie-AngeSohn, Joo HyukVuylsteke, PeterHarnden, Kathleen K.Khong, HungKocsis, JuditDalenc, FlorenceKaklamani, VirginiaDillon, PatrickBabu, SunilWaters, SimonDeleu, InesGarcia-Saenz, JoseBria, EmilioCazzaniga, MarinaLu, JaniceAftimos, PhilippeCortes, JavierLiu, ShubinLaurent, DirkConlan, Maureen G.Bidard, Francois-Clement
- [40] Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALDANNALS OF ONCOLOGY, 2022, 33 (07) : S638 - S638Aftimos, P. G.Cortes, J.Bidard, F. C.Kaklamani, V.Bardia, A.Neven, P.Streich, G.Montero, A.Forget, F.Reynier, M. A. MouretSohn, J.Taylor, D.Harnden, K.Khong, H.Kocsis, J.Dalenc, F.Dillon, P.Tonini, G.Grzegorzewski, K. J.Lu, J.